Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Mallinckrodt
Baxter
Dow
Moodys

Last Updated: December 10, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,947,654

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Which drugs does patent 7,947,654 protect, and when does it expire?

Patent 7,947,654 protects NOCDURNA and is included in one NDA.

This patent has forty-two patent family members in twenty-eight countries.

Summary for Patent: 7,947,654
Title:Pharmaceutical formulations
Abstract: Good bioavailability of desmopressin can be obtained by means of an orodispersible pharmaceutical dosage form. Preferred dosage forms comprise desmopressin and an open matrix network which is an inert water-soluble or water-dispersible carrier material. Desmopressin formulated in this way is useful for voiding postponement, or the treatment or prevention of incontinence, primary noctural enuresis (PNE), nocturia or central diabetes insipidus. Peptides other than desmopressin can also be formulated in this way.
Inventor(s): Nilsson; Anders (Lund, SE), Lindner; Hans (Leichlingen, DE), Wittendorff; Jorgen (Hvidovre, DK)
Assignee: Ferring B.V. (Hoofddorp, NL)
Application Number:12/487,116
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,947,654
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Drugs Protected by US Patent 7,947,654

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-001 Jun 21, 2018 RX Yes No   Start Trial   Start Trial Y   Start Trial
Ferring Pharms Inc NOCDURNA desmopressin acetate TABLET;SUBLINGUAL 022517-002 Jun 21, 2018 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,947,654

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0210397.6May 7, 2002
PCT/IB02/04036Sep 20, 2002

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Moodys
AstraZeneca
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.